Rapamicina tópica: otra opción terapéutica del angioma en penacho en el adulto

Escudero-Góngora, M.M.; Corral-Magaña, O.; Gómez, Cristina; Martín‐Santiago, A.

doi:10.1016/j.ad.2017.04.026

Cited by 3 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In previous studies, sirolimus has shown effective anti-angiogenic properties and can effectively reduce the VEGF content, so it is mostly used in the treatment of tumour diseases [20,21]. In recent years, the use of sirolimus as a drug treatment for vascular diseases such as lymphatic malformation and venous malformation was proposed [22], and a considerable number of cases have confirmed the therapeutic effect of sirolimus in different types of vascular malformations [23,24]. However, to date, medications targeting AVMs remain to be explored.…”

Section: Discussionmentioning

confidence: 98%

Potential anti-arteriovenous malformations effect of sirolimus on angiogenesis induced by maxillofacial venous hypertension

Xiao¹,

Gui²,

Han³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: This study aimed to explore the possible role and mechanism of venous hypertension (VH) in the occurrence and development of arteriovenous malformations (AVMs) and to study the therapeutic effect of VH regulation on AVMs to provide insight into AVM pathogenesis and explore new treatments.Methods: Maxillofacial VH models were established by cervical vascular anastomosis. Osteogenesis and angiogenesis in the model rats were analysed by imaging and histology, and the inhibitory effects of intraperitoneal (ip) sirolimus injection on angiogenesis were detected. The effect of sirolimus on the biological behaviour of human umbilical vein endothelial cells (HUVECs) cultured in vitro and mechanism of sirolimus were detected by cytology.Result: The local microvessel density increased, the vessels showed tortuous dilation, and mRNA and protein levels of angiogenesis-related genes were increased in venous hypertension environment. These phenomena were alleviated or eliminated by ip injection of a sirolimus solution. Sirolimus inhibited proliferation, tubule formation, migration, invasion, angiogenesis-related gene transcription and translation, and phosphorylation of mammalian target of rapamycin (mTOR) and its downstream substrate proteins S6K1 and 4EBP1.Conclusions: Abnormal angiogenesis caused by VH is related to abnormal activation of the mTOR pathway, which is important in regulating local angiogenesis; sirolimus inhibited hypertension-induced excessive angiogenesis in vivo and in vitro through the mTOR signalling pathway. This study provides a basis for further mechanistic study of AVM formation and insight into sirolimus as a possible target drug for AVM management.

show abstract

Section: Discussionmentioning

confidence: 98%

Potential anti-arteriovenous malformations effect of sirolimus on angiogenesis induced by maxillofacial venous hypertension

Xiao¹,

Gui²,

Han³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

Use of topical rapamycin in the treatment of superficial lymphatic malformations

García-Montero

Boz

Baselga-Torres

et al. 2019

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Efficacy and safety of sirolimus in the treatment of vascular anomalies: A systematic review

Freixo

Ferreira

Martins

et al. 2020

Journal of Vascular Surgery

140

115

View full text Add to dashboard Cite

Objective: The management of vascular anomalies is complex and requires a multidisciplinary team with a combination of medical, surgical, and intervention treatments. Medical treatment is limited and has conflicting results. Off-label use of mammalian target of rapamycin inhibitors shows promising results. The objective of this study was to systematically evaluate the literature published about the efficacy and safety of sirolimus in the treatment of vascular anomalies. Methods: A systematic review of the published literature was conducted using the PubMed database and Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Results: There were 73 articles included: 2 randomized controlled studies, 2 nonrandomized prospective studies, and 69 retrospective case reports and case series. In total, 373 patients were included. Sirolimus was administered topically to 56 patients and orally to 317 patients. Sirolimus was highly effective in the treatment of vascular tumors associated with Kasabach-Merritt phenomenon (95.5% of the patients clinically improved and 93% had normalization of coagulopathy), venous malformations (size reduction was observed in 88.9% of patients), and lymphatic malformations (clinical improvement in 94.9% of patients). Topical sirolimus results were conflicting. Arteriovenous malformations were not improved by sirolimus. Conclusions: Low-level evidence suggests that sirolimus can improve the prognosis of vascular anomalies, most notably vascular tumors associated with life-threatening coagulopathy and venous and lymphatic malformations. Further research is needed to establish the benefits of sirolimus in the management of vascular anomalies.

show abstract

Rapamicina tópica: otra opción terapéutica del angioma en penacho en el adulto

Cited by 3 publications

References 10 publications

Potential anti-arteriovenous malformations effect of sirolimus on angiogenesis induced by maxillofacial venous hypertension

Potential anti-arteriovenous malformations effect of sirolimus on angiogenesis induced by maxillofacial venous hypertension

Use of topical rapamycin in the treatment of superficial lymphatic malformations

Efficacy and safety of sirolimus in the treatment of vascular anomalies: A systematic review

Contact Info

Product

Resources

About